LGC Clinical Diagnostics Seraseq cfDNA NIPT Reference Materials

LGC Clinical Diagnostics has launched Seraseq Antepartum and Postpartum T21 Male and 22q11 Male cfDNA Reference Materials, designed specifically for noninvasive prenatal testing (NIPT) of fetal trisomy 21 (Down syndrome) and microdeletion 22q11 (DiGeorge syndrome). These products enable dilution of the fetal fraction to perform limit of detection studies and analytical validation. Users can also monitor their assay performance at a fetal fraction level of their choice. Derived from naturally occurring matched maternal and fetal circulating cell-free DNA, these reference materials can be used for assay development, validation, verification, analysis, and routine monitoring of test performance, LGC said. The materials are supplied as purified cfDNA in 0.1X TE buffer for ease of use during library preparation, the company added.